Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

The United States Food and Drug Administration (FDA) has suspended Valneva SE’s license for IXCHIQ, citing four new reports ...

On August 25, 2025, Valneva announced that the FDA suspended the license for its chikungunya vaccine, IXCHIQ®, in the U.S. due to four new reports of serious adverse events. This suspension requires ...

Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Valneva (VALN) stock in focus as the FDA suspends its chikungunya vaccine Ixchiq due to safety issues, including deaths. Read ...

U.S. suspends Ixchiq vaccine license due to serious side effects, raising concerns over chikungunya virus spread globally.